Business
LGC Capital Signs Definitive Agreement to Acquire Strategic Interest in Licenced Australian Medical Cannabis Company - Little Green Pharma
LGC Capital Signs Definitive Agreement to Acquire Strategic Interest in Licenced Australia...
About this update from Elixxer Ltd.
[{"type":"text","content":"\n\n\n\nLGC Capital Signs Definitive Agreement to Acquire Strategic Interest in Licenced Australian Medical Cannabis Company - Little Green Pharma\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nMONTREAL, Oct. 5, 2017\n\n\n\n- TSX Venture Exchange authorizes LGC to proceed to closing of the transaction, scheduled for Tuesday, October 10, 2017\n\n\n\nMONTREAL, Oct. 5, 2017 /CNW/ - LGC Capital Ltd. (TSXV: LG) (\"LGC\") is pleased to announce that it has entered into a definitive Subscription Agreement with licenced Australian Medical Cannabis company Habi Pharma Pty Ltd of Perth, Australia, doing business as \"Little Green Pharma\", for the acquisition of a strategic interest in Little Green Pharma, as announced on September 26, 2017. LGC is also pleased to announce that the TSX Venture Exchange has authorized LGC to proceed to the closing of the transaction, which is scheduled to take place on Tuesday, October 10, 2017.\n\nLittle Green Pharma is one of the few licenced companies in Australia authorized to cultivate and produce Medical Cannabis within Australia.\n\nLittle Green Pharma (www.lgpharma.com.au) has advised LGC that it plans to commence cultivation and production of one of the first clean locally-grown Medical Cannabis products for use solely within Australia, giving hope and relief to those suffering from certain debilitating illnesses. Little Green Pharma's patented technology aims to control the medicinal cannabis particle size encapsulated in the liposomes to optimise the bio-availability so the cannabinoids are readily absorbed into the bloodstream. This enables the resulting preparation to achieve desired therapeutic results with significantly lower cannabinoid doses, when compared to other forms of medicinal cannabis. Little Green Pharma's patented process significantly reduces production costs, enabling Little Green Pharma to be more competitive in the market.\n\n\"The signing of a definitive Subscription Agreement and approval by the TSX Venture Exchange to acquire this strategic initial interest in Little Gre...